Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5)

被引：0
|
作者：
E Schuler
A Giagounidis
D Haase
K Shirneshan
G Büsche
U Platzbecker
F Nolte
K Götze
R F Schlenk
A Ganser
A Letsch
F Braulke
M Lübbert
G Bug
P Schafhausen
U Bacher
N Gattermann
M Wulfert
R Haas
U Germing
机构：
[1] Oncology and Clinical Immunology,Department for Hematology
[2] University Hospital,Department of Hematology
[3] Heinrich-Heine-University,Department of Hematology
[4] Oncology and Palliative Care,Department of Hematology and Oncology
[5] Marien Hospital Duesseldorf,Department of Internal Medicine
[6] University Medicine Goettingen,Department of Internal Medicine
[7] Clinics of Hematology and Medical Oncology,Department of Hematology
[8] Hannover Medical School,Department of Hematology and Oncology
[9] Institute of Pathology,Department of Internal Medicine
[10] University Hospital Dresd,Department of Oncology
[11] en,undefined
[12] University Hospital Mannheim,undefined
[13] Technical University of Munich,undefined
[14] University Hospital Ulm,undefined
[15] Hemostasis,undefined
[16] Oncology,undefined
[17] and Stem Cell Transplantation,undefined
[18] Hannover Medical School,undefined
[19] Charité,undefined
[20] Benjamin Franklin University,undefined
[21] University Hospital Freiburg,undefined
[22] Internal Medicine,undefined
[23] University Hospital Frankfurt,undefined
[24] Hematology,undefined
[25] BMT with section Pneumology,undefined
[26] Hubertus Wald Cancer Center,undefined
[27] University Medical Center Hamburg-Eppendorf,undefined
来源：
Leukemia | 2016年 / 30卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1580 / 1582
页数：2
相关论文
共 50 条
  • [21] Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes
    Drusbosky, Leylah M.
    Cogle, Christopher R.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (09)
  • [22] Treatment of myelodysplastic syndromes with del 5q before the lenalidomide era:: The GFM experience.
    Kelaidi, Charikleia
    Park, Sophie
    Brechignac, Sabine
    Mannone, Lionel
    Vey, Norbert
    Dombret, Herve
    Aljassem, Lina
    Starnatoullas, Aspasia
    Ades, Lionel
    Giraudier, Setphane
    de Botton, Stephane
    Mahe, Beatrice
    Lepelley, Pascale
    Picard, Fracoise
    Leroux, Genevieve
    Daniel, Marie-Threrese
    Bouscary, Didier
    Dreyfus, Francois
    Fenaux, Pierre
    BLOOD, 2006, 108 (11) : 757A - 757A
  • [23] A Calcium-Dependent Pathway Determines Response to Lenalidomide in Del(5q) Myelodysplastic Syndromes
    Fang, Jing
    Liu, Xiaona
    Bolanos, Lyndsey
    Barker, Brenden
    Rigolino, Carmela
    Cortelezzi, Agostino
    Oliva, Esther Natalie
    MacBeth, Kyle J.
    Komurov, Kakajan
    Starczynowski, Daniel T.
    BLOOD, 2014, 124 (21)
  • [24] The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
    Sekeres, Mikkael A.
    Swern, Arlene S.
    Giagounidis, Aristoteles
    List, Alan F.
    Selleslag, Dominik
    Mittelman, Moshe
    Schlegelberger, Brigitte
    Goehring, Gudrun
    Li, Jack Shiansong
    Sugrue, Mary M.
    Fenaux, Pierre
    BLOOD CANCER JOURNAL, 2018, 8
  • [25] The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
    Mikkael A. Sekeres
    Arlene S. Swern
    Aristoteles Giagounidis
    Alan F. List
    Dominik Selleslag
    Moshe Mittelman
    Brigitte Schlegelberger
    Gudrun Göhring
    Jack Shiansong Li
    Mary M. Sugrue
    Pierre Fenaux
    Blood Cancer Journal, 8
  • [26] Clonal evolution in myelodysplastic syndromes with isolated del(5q): the importance of genetic monitoring
    Jaedersten, Martin
    Karsan, Aly
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (02): : 177 - 180
  • [27] Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
    Butrym, Aleksandra
    Lech-Maranda, Ewa
    Patkowska, Elzbieta
    Kumiega, Beata
    Bieniaszewska, Maria
    Mital, Andrzej
    Madry, Krzysztof
    Torosian, Tigran
    Wichary, Ryszard
    Rybka, Justyna
    Warzocha, Krzysztof
    Mazur, Grzegorz
    BMC CANCER, 2015, 15
  • [28] Survival of patients with de novo myelodysplastic syndromes (MDS) and del(5q)
    Gritsaev, S.
    Martinkevitch, I.
    Petrova, E.
    Kostroma, I.
    Ivanova, M.
    Sergeev, A.
    Tiranova, S.
    Potichonova, N.
    LEUKEMIA RESEARCH, 2013, 37 : S88 - S88
  • [29] Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy
    Oliva, Esther N.
    Latagliata, Roberto
    Lagana, Carmelo
    Breccia, Massimo
    Galimberti, Sara
    Morabito, Fortunato
    Poloni, Antonella
    Balleari, Enrico
    Cortelezzi, Agostino
    Palumbo, Giuseppe
    Sanpaolo, Grazia
    Volpe, Antonio
    Specchia, Giorgina
    Finelli, Carlo
    D'Errigo, Maria Grazia
    Roda, Filippo
    Alati, Caterina
    Alimena, Giuliana
    Nobile, Francesco
    Spiriti, Maria A. Aloe
    LEUKEMIA & LYMPHOMA, 2013, 54 (11) : 2458 - 2465
  • [30] Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
    Aleksandra Butrym
    Ewa Lech-Maranda
    Elżbieta Patkowska
    Beata Kumiega
    Maria Bieniaszewska
    Andrzej Mital
    Krzysztof Madry
    Tigran Torosian
    Ryszard Wichary
    Justyna Rybka
    Krzysztof Warzocha
    Grzegorz Mazur
    BMC Cancer, 15
12345